Canaccord Genuity Reiterates a 'Buy' on Heartware Int'l (HTWR); Huge Q1 on Top Share in OUS

May 11, 2012 9:31 AM EDT Send to a Friend
Get Alerts HTWR Hot Sheet
Price: $85.47 -0.11%

Rating Summary:
    11 Buy, 6 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 20 | Down: 10 | New: 7
Trade HTWR Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target raised from $95 to $101.

Analyst, Jason R. Mills, said, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."

"We raise our 2012 sales/loss per share (LPS) estimates to $134.4M/$(4.65) from $125.5M/$(5.06)."

For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.

Shares of Heartware Int'l closed at $77.14 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Add Your Comment